[18F]AlF-NOTA-FAPI-04 PET/CT in Inflammation and Fibrosis in Renal Diseases

Clinical Study of Fibroblast Activating Protein Inhibitor (FAPI) -Mediated 18F Targeted to Evaluate Inflammation and Fibrosis in Renal Diseases

The goal of this observational study is to explore the feasibility of using 18F-labeled FAP molecular probe for PET/CT imaging (18F-FAPI PET/CT) to accurately evaluate inflammation and fibrosis in renal diseases. The main questions it aims to answer are:

• Can 18F-FAPI PET/CT accurately evaluate the inflammation and fibrosis of kidney disease?
• What is the value of 18F-FAPI PET/CT as a non-invasive assessment of inflammation and fibrosis in kidney disease? Participants will receive [18F]AlF-NOTA-FAPI-04 PET/CT and renal aspiration biopsy.

Inclusion Criteria:

• The pitients of nephritis or fibrosis disease

Exclusion Criteria:

• Hypertension that is difficult to control with medication, and systolic blood pressure exceeding 160mmHg
• Renal biopsy cannot be performed for severe exclotting disease
• Complicated with chronic liver disease, myocardial infarction, stroke, and malignant tumor
• Unable to cooperate with renal puncture biopsy due to language communication or other problems
• Female patients who are pregnant (or attempting to become pregnant within six months), breastfeeding, or unwilling to use contraception
• Abnormal cardiopulmonary function or mental state, unable to tolerate prone lying for 20 minutes
• Alcohol allergy
• Patients with significant decrease in urine volume due to disease
• Refusal to sign an informed consent form or inability or unwillingness to comply with the investigator-approved protocol
• Other circumstances deemed inappropriate by the investigator for participation in the study.